Primary Childrens Medical Center
Welcome,         Profile    Billing    Logout  
 1 Trial 
14 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Clauss, Sarah
ORION-20, NCT06597019: Study to Evaluate Efficacy and Safety of Inclisiran in Children With Heterozygous Familial Hypercholesterolemia

Recruiting
3
51
Europe, US, RoW
Inclisiran, KJX839, Placebo, saline solution
Novartis Pharmaceuticals
Familial Hypercholesterolemia - Heterozygous
03/28
04/29
ORION-19, NCT06597006: Study to Evaluate Safety, Tolerability and Efficacy of Inclisiran in Children With Homozygous Familial Hypercholesterolemia

Recruiting
3
9
Europe, US, RoW
Inclisiran, KJX839, Placebo, saline solution
Novartis Pharmaceuticals
Familial Hypercholesterolemia - Homozygous
03/28
04/29
NPC-QIC, NCT02852031: National Collaborative to Improve Care of Children With Complex Congenital Heart Disease

Recruiting
N/A
1000
Europe, Canada, US
Collaborative Learning Network
Children's Hospital Medical Center, Cincinnati
Hypoplastic Left Heart Syndrome (HLHS)
05/26
05/28
Youssef, Rasha
SURPASS-EARLY, NCT05433584: A Study of Tirzepatide Compared With Intensified Conventional Care in Adult Participants With Type 2 Diabetes

Active, not recruiting
4
780
Europe, Canada, US, RoW
Tirzepatide, LY3298176, Antihyperglycemic medication
Eli Lilly and Company
Type 2 Diabetes
10/25
11/27
TRAILBLAZER-ALZ 6, NCT05738486: A Study of Different Donanemab (LY3002813) Dosing Regimens in Adults With Early Alzheimer's Disease

Active, not recruiting
3
1100
Europe, US
Donanemab, LY3002813, Placebo, Dexamethasone
Eli Lilly and Company
Alzheimer's Disease, Dementia, Brain Diseases, Central Nervous System Diseases, Nervous System Diseases, Neurodegenerative Diseases, Neurocognitive Disorders, Mental Disorders
05/24
05/25
NCT06383390: The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes)

Recruiting
3
10000
Europe, Canada, US, RoW
Retatrutide, LY3437943, Placebo
Eli Lilly and Company
Atherosclerotic Cardiovascular Disease (ASCVD), Chronic Kidney Disease (CKD)
02/29
02/29
APG-20 OLE, NCT06679270: Open-label Extension Study to Evaluate Metreleptin in Patients With Partial Lipodystrophy

Recruiting
3
15
US
Metreleptin
Amryt Pharma
Familial Partial Lipodystrophy
03/28
03/28
ORION-20, NCT06597019: Study to Evaluate Efficacy and Safety of Inclisiran in Children With Heterozygous Familial Hypercholesterolemia

Recruiting
3
51
Europe, US, RoW
Inclisiran, KJX839, Placebo, saline solution
Novartis Pharmaceuticals
Familial Hypercholesterolemia - Heterozygous
03/28
04/29
METRE-PL, NCT05164341: Study to Evaluate the Safety and Efficacy of Daily Subcutaneous Metreleptin Treatment in Subjects With PL

Recruiting
3
65
Europe, Canada, US, RoW
metreleptin, Placebo
Amryt Pharma
Partial Lipodystrophy
06/25
01/26
TRIUMPH-2, NCT05929079: A Study of Retatrutide (LY3437943) in Participants With Type 2 Diabetes Mellitus Who Have Obesity or Overweight

Active, not recruiting
3
1000
Europe, US, RoW
Retatrutide, LY3437943, Placebo
Eli Lilly and Company
Type 2 Diabetes, Obesity, Overweight, Obstructive Sleep Apnea
05/26
05/26
NCT05026866: A Donanemab (LY3002813) Study in Participants With Preclinical Alzheimer's Disease (TRAILBLAZER-ALZ 3)

Recruiting
3
2996
Japan, US
Donanemab, LY3002813, Placebo
Eli Lilly and Company
Alzheimer Disease
11/27
11/27
NCT06538116: A Study of Mevidalen (LY3154207) in Participants With Alzheimer's Disease

Recruiting
2
300
Japan, US
Mevidalen, LY3154207, Placebo
Eli Lilly and Company
Alzheimer Disease
12/25
01/26
NCT06031844: A Study to Investigate the Efficacy, Safety, and Tolerability of DFV890 for Inflammatory Marker Reduction in Adult Participants With Coronary Heart Disease and Elevated hsCRP

Completed
2
24
Canada, US
DFV890, Placebo
Novartis Pharmaceuticals
Coronary Heart Disease
12/24
12/24
Tribble, Hilariann
ORION-20, NCT06597019: Study to Evaluate Efficacy and Safety of Inclisiran in Children With Heterozygous Familial Hypercholesterolemia

Recruiting
3
51
Europe, US, RoW
Inclisiran, KJX839, Placebo, saline solution
Novartis Pharmaceuticals
Familial Hypercholesterolemia - Heterozygous
03/28
04/29
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Clauss, Sarah
ORION-20, NCT06597019: Study to Evaluate Efficacy and Safety of Inclisiran in Children With Heterozygous Familial Hypercholesterolemia

Recruiting
3
51
Europe, US, RoW
Inclisiran, KJX839, Placebo, saline solution
Novartis Pharmaceuticals
Familial Hypercholesterolemia - Heterozygous
03/28
04/29
ORION-19, NCT06597006: Study to Evaluate Safety, Tolerability and Efficacy of Inclisiran in Children With Homozygous Familial Hypercholesterolemia

Recruiting
3
9
Europe, US, RoW
Inclisiran, KJX839, Placebo, saline solution
Novartis Pharmaceuticals
Familial Hypercholesterolemia - Homozygous
03/28
04/29
NPC-QIC, NCT02852031: National Collaborative to Improve Care of Children With Complex Congenital Heart Disease

Recruiting
N/A
1000
Europe, Canada, US
Collaborative Learning Network
Children's Hospital Medical Center, Cincinnati
Hypoplastic Left Heart Syndrome (HLHS)
05/26
05/28
Youssef, Rasha
SURPASS-EARLY, NCT05433584: A Study of Tirzepatide Compared With Intensified Conventional Care in Adult Participants With Type 2 Diabetes

Active, not recruiting
4
780
Europe, Canada, US, RoW
Tirzepatide, LY3298176, Antihyperglycemic medication
Eli Lilly and Company
Type 2 Diabetes
10/25
11/27
TRAILBLAZER-ALZ 6, NCT05738486: A Study of Different Donanemab (LY3002813) Dosing Regimens in Adults With Early Alzheimer's Disease

Active, not recruiting
3
1100
Europe, US
Donanemab, LY3002813, Placebo, Dexamethasone
Eli Lilly and Company
Alzheimer's Disease, Dementia, Brain Diseases, Central Nervous System Diseases, Nervous System Diseases, Neurodegenerative Diseases, Neurocognitive Disorders, Mental Disorders
05/24
05/25
NCT06383390: The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes)

Recruiting
3
10000
Europe, Canada, US, RoW
Retatrutide, LY3437943, Placebo
Eli Lilly and Company
Atherosclerotic Cardiovascular Disease (ASCVD), Chronic Kidney Disease (CKD)
02/29
02/29
APG-20 OLE, NCT06679270: Open-label Extension Study to Evaluate Metreleptin in Patients With Partial Lipodystrophy

Recruiting
3
15
US
Metreleptin
Amryt Pharma
Familial Partial Lipodystrophy
03/28
03/28
ORION-20, NCT06597019: Study to Evaluate Efficacy and Safety of Inclisiran in Children With Heterozygous Familial Hypercholesterolemia

Recruiting
3
51
Europe, US, RoW
Inclisiran, KJX839, Placebo, saline solution
Novartis Pharmaceuticals
Familial Hypercholesterolemia - Heterozygous
03/28
04/29
METRE-PL, NCT05164341: Study to Evaluate the Safety and Efficacy of Daily Subcutaneous Metreleptin Treatment in Subjects With PL

Recruiting
3
65
Europe, Canada, US, RoW
metreleptin, Placebo
Amryt Pharma
Partial Lipodystrophy
06/25
01/26
TRIUMPH-2, NCT05929079: A Study of Retatrutide (LY3437943) in Participants With Type 2 Diabetes Mellitus Who Have Obesity or Overweight

Active, not recruiting
3
1000
Europe, US, RoW
Retatrutide, LY3437943, Placebo
Eli Lilly and Company
Type 2 Diabetes, Obesity, Overweight, Obstructive Sleep Apnea
05/26
05/26
NCT05026866: A Donanemab (LY3002813) Study in Participants With Preclinical Alzheimer's Disease (TRAILBLAZER-ALZ 3)

Recruiting
3
2996
Japan, US
Donanemab, LY3002813, Placebo
Eli Lilly and Company
Alzheimer Disease
11/27
11/27
NCT06538116: A Study of Mevidalen (LY3154207) in Participants With Alzheimer's Disease

Recruiting
2
300
Japan, US
Mevidalen, LY3154207, Placebo
Eli Lilly and Company
Alzheimer Disease
12/25
01/26
NCT06031844: A Study to Investigate the Efficacy, Safety, and Tolerability of DFV890 for Inflammatory Marker Reduction in Adult Participants With Coronary Heart Disease and Elevated hsCRP

Completed
2
24
Canada, US
DFV890, Placebo
Novartis Pharmaceuticals
Coronary Heart Disease
12/24
12/24
Tribble, Hilariann
ORION-20, NCT06597019: Study to Evaluate Efficacy and Safety of Inclisiran in Children With Heterozygous Familial Hypercholesterolemia

Recruiting
3
51
Europe, US, RoW
Inclisiran, KJX839, Placebo, saline solution
Novartis Pharmaceuticals
Familial Hypercholesterolemia - Heterozygous
03/28
04/29

Download Options